Despite the well-documented relationship between lobar cerebral microbleeds (lCMB) and Alzheimer’s disease (AD), there is limited knowledge about the role of lCMB in AD pathology.
Objective:
To understand the nature of this relationship, we investigated the association between lCMB, amyloid load, perfusion, and metabolism.
Methods:
Participants with AD, mild cognitive impairment (MCI), and healthy controls were recruited and scanned with 11C-Pittsburg-Compound B (PiB), Fluorodeoxyglucose (FDG) PET, and susceptibility-weighted MRI. Early PiB-PET frames were used to estimate perfusion. The association between lCMB and PET uptake in each anatomical lobe was measured using multiple regression models.
Results:
The presence of lCMB predicted increased total (p < 0.001) and regional (p = 0.0002) PiB uptake, as well as decreased cerebral perfusion (p = 0.03). Cases with lCMB had hypometabolism in their temporal lobe (p = 0.04).
Conclusion:
There are significant relationships between lCMBs and various markers of AD pathology. lCMB has a spatial association with Aβ load and a complex effect on perfusion and metabolism.
AzarpazhoohMR, AvanA, CiprianoLE, MunozDG, SposatoLA, HachinskiV (2018) Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimers Dement14, 148–156.
2.
KloppenborgRP, NederkoornPJ, GeerlingsMI, van den BergE (2014) Presence and progression of white matter hyperintensities and cognition: A meta-analysis. Neurology82, 2127–2138.
SperlingR, SallowayS, BrooksDJ, TampieriD, BarakosJ, FoxNC, RaskindM, SabbaghM, HonigLS, PorsteinssonAP, LieberburgI, ArrighiHM, MorrisKA, LuY, LiuE, GreggKM, BrashearHR, KinneyGG, BlackR, GrundmanM (2012) Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol11, 241–249.
7.
JellingerKA (2002) Alzheimer disease and cerebrovascular pathology: An update. J Neural Transm (Vienna)109, 813–836.
8.
JohnsonKA, GregasM, BeckerJA, KinnecomC, SalatDH, MoranEK, SmithEE, RosandJ, RentzDM, KlunkWE, MathisCA, PriceJC, DekoskyST, FischmanAJ, GreenbergSM (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol62, 229–234.
9.
LyJV, DonnanGA, VillemagneVL, ZavalaJA, MaH, O’KeefeG, GongSJ, GunawanRM, SaunderT, AckermanU, Tochon-DanguyH, ChurilovL, PhanTG, RoweCC (2010) 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology74, 487–493.
10.
SparaciaG, AgnelloF, La TonaG, IaiaA, MidiriF, SparaciaB (2017) Assessment of cerebral microbleeds by susceptibility-weighted imaging in Alzheimer’s disease patients: A neuroimaging biomarker of the disease. Neuroradiol J30, 330–335.
11.
ChiangGC, Cruz HernandezJC, KantarciK, JackCRJr, WeinerMW (2015) Cerebral microbleeds, CSF p-Tau, and cognitive decline: Significance of anatomic distribution. AJNR Am J Neuroradiol36, 1635–1641.
12.
BasselerieH, BracoudL, ZeestratenE, BouguenE, KiyasovaV, PueyoM, CognardC, DumasH, GramadaR, OussetPJ, VellasB, BonnevilleF (2017) Incident cerebral microbleeds detected by susceptibility weight-imaging help to identify patients with mild cognitive impairment progressing to Alzheimer’s disease. J Alzheimers Dis60, 253–262.
13.
Rodriguez-VieitezE, CarterSF, ChiotisK, Saint-AubertL, LeuzyA, SchollM, AlmkvistO, WallA, LangstromB, NordbergA (2016) Comparison of early-phase 11C-deuterium-l-deprenyl and 11C-Pittsburgh compound B PET for assessing brain perfusion in Alzheimer disease. J Nucl Med57, 1071–1077.
RostomianAH, MadisonC, RabinoviciGD, JagustWJ (2011) Early 11C-PIB frames and 18F-FDG PET measures are comparable: A study validated in a cohort of AD and FTLD patients. J Nucl Med52, 173–179.
16.
McNameeRL, YeeSH, PriceJC, KlunkWE, RosarioB, WeissfeldL, ZiolkoS, BergincM, LoprestiB, DekoskyS, MathisCA (2009) Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med50, 348–355.
17.
Kinahan PERJ (1989) Analytic 3D image reconstruction using all detected events - IEEE Journals & Magazine. IEEE Trans Nucl Sci36, 964–968.
18.
AvantsBB, TustisonNJ, SongG, CookPA, KleinA, GeeJC (2011) A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage54, 2033–2044.
19.
GousiasIS, RueckertD, HeckemannRA, DyetLE, BoardmanJP, EdwardsAD, HammersA (2008) Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest. Neuroimage40, 672–684.
MevelK, DesgrangesB, BaronJC, LandeauB, De la SayetteV, ViaderF, EustacheF, ChetelatG (2007) Detecting hippocampal hypometabolism in Mild Cognitive Impairment using automatic voxel-based approaches. Neuroimage37, 18–25.
22.
GregoireSM, ChaudharyUJ, BrownMM, YousryTA, KallisC, JagerHR, WerringDJ (2009) The Microbleed Anatomical Rating Scale (MARS): Reliability of a tool to map brain microbleeds. Neurology73, 1759–1766.
23.
BacskaiBJ, FroschMP, FreemanSH, RaymondSB, AugustinackJC, JohnsonKA, IrizarryMC, KlunkWE, MathisCA, DekoskyST, GreenbergSM, HymanBT, GrowdonJH (2007) Molecular imaging with Pittsburgh Compound B confirmed at autopsy: A case report. Arch Neurol64, 431–434.
24.
IkonomovicMD, KlunkWE, AbrahamsonEE, MathisCA, PriceJC, TsopelasND, LoprestiBJ, ZiolkoS, BiW, PaljugWR, DebnathML, HopeCE, IsanskiBA, HamiltonRL, DeKoskyST (2008) Post-mortem correlates ofPiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain131, 1630–1645.
25.
LockhartA, LambJR, OsredkarT, SueLI, JoyceJN, YeL, LibriV, LeppertD, BeachTG (2007) PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain130, 2607–2615.
26.
DierksenGA, SkehanME, KhanMA, JengJ, NandigamRN, BeckerJA, KumarA, NealKL, BetenskyRA, FroschMP, RosandJ, JohnsonKA, ViswanathanA, SalatDH, GreenbergSM (2010) Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol68, 545–548.
27.
YatesPA, SirisriroR, VillemagneVL, FarquharsonS, MastersCL, RoweCC (2011) Cerebral microhemorrhage and brain beta-amyloid in aging and Alzheimer disease. Neurology77, 48–54.
28.
TsaiHH, TsaiLK, ChenYF, TangSC, LeeBC, YenRF, JengJS (2017) Correlation of cerebral microbleed distribution to amyloid burden in patients with primary intracerebral hemorrhage. Sci Rep7, 44715.
29.
BlomquistG, EnglerH, NordbergA, RingheimA, WallA, ForsbergA, EstradaS, FrandbergP, AntoniG, LangstromB (2008) Unidirectional influx and net accumulation of PIB. Open Neuroimag J2, 114–125.
30.
ForsbergA, EnglerH, BlomquistG, LangstromB, NordbergA (2012) The use of PIB-PET as a dual pathological and functional biomarker in AD. Biochim Biophys Acta1822, 380–385.
31.
ChungYA, OJH, KimJY, KimKJ, AhnKJ (2009) Hypoperfusion and ischemia in cerebral amyloid angiopathy documented by 99mTc-ECD brain perfusion SPECT. J Nucl Med50, 1969–1974.
32.
MaierFC, WehrlHF, SchmidAM, MannheimJG, WiehrS, LerdkraiC, CalaminusC, StahlschmidtA, YeL, BurnetM, StillerD, SabriO, ReischlG, StaufenbielM, GaraschukO, JuckerM, PichlerBJ (2014) Longitudinal PET-MRI reveals beta-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nat Med20, 1485–1492.
33.
DaiW, LopezOL, CarmichaelOT, BeckerJT, KullerLH, GachHM (2009) Mild cognitive impairment and Alzheimer disease: Patterns of altered cerebral blood flow at MR imaging. Radiology250, 856–866.
34.
DingB, LingHW, ZhangY, HuangJ, ZhangH, WangT, YanFH (2014) Pattern of cerebral hyperperfusion in Alzheimer’s disease and amnestic mild cognitive impairment using voxel-based analysis of 3D arterial spin-labeling imaging: Initial experience. Clin Interv Aging9, 493–500.
35.
BangenKJ, RestomK, LiuTT, WierengaCE, JakAJ, SalmonDP, BondiMW (2012) Assessment of Alzheimer’s disease risk with functional magnetic resonance imaging: An arterial spin labeling study. J Alzheimers Dis31Suppl 3, S59–74.
KalariaRN (1997) Cerebrovascular degeneration is related to amyloid-beta protein deposition in Alzheimer’s disease. Ann N Y Acad Sci826, 263–271.
41.
SamurakiM, MatsunariI, YoshitaM, ShimaK, Noguchi-ShinoharaM, HamaguchiT, OnoK, YamadaM (2015) Cerebral amyloid angiopathy-related microbleeds correlate with glucose metabolism and brain volume in Alzheimer’s disease. J Alzheimers Dis48, 517–528.
42.
MerliniM, MeyerEP, Ulmann-SchulerA, NitschRM (2011) Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol122, 293–311.
43.
WellerRO, SubashM, PrestonSD, MazantiI, CarareRO (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol18, 253–266.
44.
GurolME, ViswanathanA, GidicsinC, HeddenT, Martinez-RamirezS, DumasA, VashkevichA, AyresAM, AurielE, van EttenE, BeckerA, CarmasinJ, SchwabK, RosandJ, JohnsonKA, GreenbergSM (2013) Cerebral amyloid angiopathy burden associated with leukoaraiosis: A positron emission tomography/magnetic resonance imaging study. Ann Neurol73, 529–536.
45.
CohenAD, PriceJC, WeissfeldLA, JamesJ, RosarioBL, BiW, NebesRD, SaxtonJA, SnitzBE, AizensteinHA, WolkDA, DeKoskyST, MathisCA, KlunkWE (2009) Basal cerebral metabolism may modulate the cognitive effects of aβ in mild cognitive impairment: An example of brain reserve. J Neurosci29, 14770.
46.
FoxPT, RaichleME (1986) Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. Proc Natl Acad Sci U S A83, 1140–1144.
47.
AlsopDC, DaiW, GrossmanM, DetreJA (2010) Arterial spin labeling blood flow MRI: Its role in the early characterization of Alzheimer’s disease. J Alzheimers Dis20, 871–880.
